Showing 10,021 - 10,040 results of 18,480 for search 'significantly ((((a decrease) OR (((greatest decrease) OR (mean decrease))))) OR (linear decrease))', query time: 0.65s Refine Results
  1. 10021

    Table 2_Global burden of low back pain and its attributable risk factors from 1990 to 2021: a comprehensive analysis from the global burden of disease study 2021.docx by Yue Li (102191)

    Published 2024
    “…The LBP burden varied by the sociodemographic index quintile and GBD region, with the highest ASIR and ASDALYsR observed in Central Europe and the greatest decrease in East Asia. Globally, women bear a higher burden of LBP than men, with middle-aged populations experiencing the heaviest burden. …”
  2. 10022

    Image 1_First-trimester choroid plexus-to-head ratio: a novel sonographic marker for the early detection of fetal central nervous system malformations.jpeg by Xianghua Xue (22563098)

    Published 2025
    “…Fetuses with microcephaly showed a significantly higher CPA/HA ratio (p < 0.001), higher CPL/OFD ratio (p < 0.001), and lower HC/AC ratio (p < 0.05).…”
  3. 10023

    Image 2_First-trimester choroid plexus-to-head ratio: a novel sonographic marker for the early detection of fetal central nervous system malformations.jpeg by Xianghua Xue (22563098)

    Published 2025
    “…Fetuses with microcephaly showed a significantly higher CPA/HA ratio (p < 0.001), higher CPL/OFD ratio (p < 0.001), and lower HC/AC ratio (p < 0.05).…”
  4. 10024

    Table 1_Impact of repeated in-vitro bacterial culture on virulence and antibiotic resistance characteristics: a study of Gram-positive and Gram-negative fish pathogens.docx by Angana Bag (21398267)

    Published 2025
    “…The fish pathogenic bacterial isolates, namely Lactococcus lactis, Enterococcus gallinarum, Proteus penneri, and Escherichia coli, underwent 56 consecutive subcultures in tryptic soy broth and were evaluated for virulence, antimicrobial susceptibility, and AMR gene expression. The results revealed a significant decrease in the virulence of Gram-positive pathogens. …”
  5. 10025

    Data Sheet 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf by figshare admin frontiersin (4545187)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  6. 10026

    Data Sheet 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  7. 10027

    Data Sheet 1_Microbial and molecular signatures for enhanced gut health in pigs fed a diet with spray-dried plasma as functional protein source.docx by Soumya K. Kar (4600924)

    Published 2025
    “…We report a significant (P < 0.05) decrease in the relative abundance of the Sarcina genera in the small intestine, an effect comparable to pharmaceutical concentrations of zinc oxide (ZnO). …”
  8. 10028
  9. 10029

    Data Sheet 2_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysi... by Jiahui Qiu (7420130)

    Published 2025
    “…</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  10. 10030

    Data Sheet 1_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysi... by Jiahui Qiu (7420130)

    Published 2025
    “…</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  11. 10031

    Table 1_Immune checkpoint proteins are associated with persistently high liver stiffness after successful HCV treatment in people with HIV: a retrospective study.docx by Rubén Martín-Escolano (17411991)

    Published 2024
    “…Although LSM values showed a decreasing trend over the years following successful HCV treatment, this trend was not statistically significant due to substantial variability among PWH. …”
  12. 10032

    Data Sheet 1_Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial.pdf by Li-qin Meng (20633030)

    Published 2025
    “…</p>Results<p>Following treatment, FFDS demonstrated significant improvements in serum triglyceride levels (P = 0.013) and a reduction in the frequency of angina episodes (P = 0.021). …”
  13. 10033

    <i>ADH7, FABP5, ALDH1A1, CRABP-2, PPARγ</i> and <i>VEGFA</i> mRNA and ADH7, FABP5, CRABP-2, PPARγ and VEGFA protein levels in limbal stromal cells (LSCs) and aniridia limbal stroma... by Shuailin Li (11907158)

    Published 2025
    “…<i>ADH7, FABP5</i> and <i>VEGFA</i> mRNA levels were significantly higher in AN-LSCs, than in LSCs (p ≤ 0.037) while ADH7 protein level was significantly lower in AN-LSCs, than in LSCs (p = 0.022) <b>(A, B, D, O)</b>. …”
  14. 10034

    Supplementary file 1_Effect of Bifidobacterium longum subsp. infantis YLGB-1496 on common diseases in pediatrics: a randomized, blinded, placebo-controlled trial.docx by Xi Zhang (83736)

    Published 2025
    “…</p>Conclusion<p>Daily administration of YLGB-1496 at a dosage of 1.5 × 10<sup>10</sup> CFU for 3 months significantly reduced the episodes of cough, fever, dry stool (defined as Bristol stool scale type 1–3), and eczematous changes of the skin. …”
  15. 10035

    Table1_Berberine alleviates ETEC-induced intestinal inflammation and oxidative stress damage by optimizing intestinal microbial composition in a weaned piglet model.docx by Yue Wang (65477)

    Published 2024
    “…A correlation analysis showed that berberine significantly increased the relative abundance of beneficial bacteria (Gemmiger, Pediococcus, Levilactobacillus, Clostridium, Lactiplantibacillus, Weissella, Enterococcus, Blautia, and Butyricicoccus) and decreased that of pathogenic bacteria (Prevotella, Streptococcus, Parabacteroides, Flavonifractor, Alloprevotella) known to be closely related to intestinal inflammation and oxidative stress in piglets. …”
  16. 10036

    Parameters of Tissue Doppler Echocardiography. by Mina Farshidgohar (20308230)

    Published 2025
    “…</p><p>Results</p><p>Out of 50 patients, two showed a decrease in left ventricular ejection fraction (LVEF) below the normal range (<55%) one month post-treatment, along with significant increases in Troponin I levels. …”
  17. 10037

    Table 1_Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial.docx by Hiroo Fukada (5154824)

    Published 2025
    “…The dapagliflozin group showed additional benefits, with significant decreases in BMI and HbA1c, γ-GT, ferritin, LDL cholesterol, and body fat levels, indicating improved glycemic control and lipid profile. …”
  18. 10038

    Table1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

    Published 2024
    “…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”
  19. 10039

    Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

    Published 2024
    “…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”
  20. 10040

    Table2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

    Published 2024
    “…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”